Wendy Freebern

563 total citations
27 papers, 392 citations indexed

About

Wendy Freebern is a scholar working on Immunology, Molecular Biology and Oncology. According to data from OpenAlex, Wendy Freebern has authored 27 papers receiving a total of 392 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Immunology, 9 papers in Molecular Biology and 9 papers in Oncology. Recurrent topics in Wendy Freebern's work include Immunotoxicology and immune responses (7 papers), Immunotherapy and Immune Responses (6 papers) and Animal testing and alternatives (5 papers). Wendy Freebern is often cited by papers focused on Immunotoxicology and immune responses (7 papers), Immunotherapy and Immune Responses (6 papers) and Animal testing and alternatives (5 papers). Wendy Freebern collaborates with scholars based in United States, Germany and United Kingdom. Wendy Freebern's co-authors include Edward G. Niles, Philip T. LoVerde, Ahmed M. Osman, Kevin Gardner, Cynthia M. Haggerty, James L. Smith, Irene Collins, Marcelo Rosado Fantappíé, Hervé Lebrec and Gadisetti V.R. Chandramouli and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Blood.

In The Last Decade

Wendy Freebern

27 papers receiving 390 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Wendy Freebern United States 11 177 96 81 75 59 27 392
Thomas G. Douglass United States 11 179 1.0× 130 1.4× 34 0.4× 65 0.9× 33 0.6× 19 454
Xiaojin Xie China 10 213 1.2× 159 1.7× 15 0.2× 33 0.4× 32 0.5× 15 471
Maria A. Whitehead United Kingdom 9 235 1.3× 150 1.6× 16 0.2× 113 1.5× 70 1.2× 12 520
S. Zanotta Italy 14 296 1.7× 47 0.5× 22 0.3× 29 0.4× 45 0.8× 18 506
Susanne Larsson Sweden 8 300 1.7× 84 0.9× 14 0.2× 51 0.7× 25 0.4× 15 608
Shao-bing Hua United States 14 408 2.3× 57 0.6× 42 0.5× 99 1.3× 44 0.7× 22 583
David Lemus Chile 10 182 1.0× 122 1.3× 43 0.5× 45 0.6× 33 0.6× 23 442
L.H. Tessier France 8 378 2.1× 15 0.2× 20 0.2× 44 0.6× 56 0.9× 12 462
Uwe Eberspaecher Germany 8 263 1.5× 34 0.4× 8 0.1× 38 0.5× 73 1.2× 10 483

Countries citing papers authored by Wendy Freebern

Since Specialization
Citations

This map shows the geographic impact of Wendy Freebern's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wendy Freebern with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wendy Freebern more than expected).

Fields of papers citing papers by Wendy Freebern

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wendy Freebern. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wendy Freebern. The network helps show where Wendy Freebern may publish in the future.

Co-authorship network of co-authors of Wendy Freebern

This figure shows the co-authorship network connecting the top 25 collaborators of Wendy Freebern. A scholar is included among the top collaborators of Wendy Freebern based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wendy Freebern. Wendy Freebern is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Grimaldi, Christine, Andrea Kießling, Benno Rattel, et al.. (2022). Current nonclinical approaches for immune assessments of immuno-oncology biotherapeutics. Drug Discovery Today. 28(2). 103440–103440. 3 indexed citations
2.
Gamse, Joshua T., et al.. (2020). Decreased immune response in monkeys administered a human T-effector cell agonist (OX40) antibody. Toxicology and Applied Pharmacology. 409. 115285–115285. 4 indexed citations
3.
MacLachlan, Timothy K., Sven Kronenberg, Nikki B. Marshall, et al.. (2020). Industry experiences with immune-mediated findings in biotherapeutic nonclinical toxicology studies. Regulatory Toxicology and Pharmacology. 119. 104825–104825. 2 indexed citations
4.
Collinge, Mark, Patricia Schneider, Dingzhou Li, et al.. (2020). Cross-company evaluation of the human lymphocyte activation assay. Journal of Immunotoxicology. 17(1). 51–58. 4 indexed citations
5.
Freebern, Wendy, et al.. (2018). Host Resistance Assays. Methods in molecular biology. 1803. 117–145. 3 indexed citations
6.
Price, Karen, Anthony M. Fletcher, Lila Ramaiah, et al.. (2018). Abstract LB-B33: Nonclinical safety evaluation of two distinct second generation variants of anti-CTLA4 monoclonal antibody, ipilimumab, in monkeys. Molecular Cancer Therapeutics. 17(1_Supplement). LB–B33. 10 indexed citations
7.
Lebrec, Hervé, Darrell R. Boverhof, Mark Collinge, et al.. (2014). The T-cell-dependent antibody response assay in nonclinical studies of pharmaceuticals and chemicals: Study design, data analysis, interpretation. Regulatory Toxicology and Pharmacology. 69(1). 7–21. 31 indexed citations
8.
Freebern, Wendy, et al.. (2012). Methods: Implementation ofin vitroandex vivophagocytosis and respiratory burst function assessments in safety testing. Journal of Immunotoxicology. 10(1). 106–117. 8 indexed citations
9.
Lebrec, Hervé, Raegan O’Lone, Wendy Freebern, Wendy Komocsar, & Peter F. Moore. (2011). Survey: Immune function and immunotoxicity assessment in dogs. Journal of Immunotoxicology. 9(1). 1–14. 12 indexed citations
10.
Freebern, Wendy. (2009). Viral Host Resistance Studies. Methods in molecular biology. 598. 109–117. 1 indexed citations
11.
Ge, Yubin, Gabriella Rustici, Wendy Freebern, et al.. (2006). Selective leukemic-cell killing by a novel functional class of thalidomide analogs. Blood. 108(13). 4126–4135. 25 indexed citations
12.
Freebern, Wendy, Cynthia M. Haggerty, Markey McNutt, et al.. (2005). Pharmacologic profiling of transcriptional targets deciphers promoter logic. The Pharmacogenomics Journal. 5(5). 305–323. 9 indexed citations
13.
McNutt, Markey, Wenwu Cui, Irene Collins, et al.. (2005). Human promoter genomic composition demonstrates non-random groupings that reflect general cellular function. BMC Bioinformatics. 6(1). 259–259. 4 indexed citations
14.
Freebern, Wendy, et al.. (2004). Profiling the expression of mitogen-induced T-cell proteins by using multi-membrane dot-blotting. Biochemical and Biophysical Research Communications. 323(1). 355–360. 5 indexed citations
15.
Freebern, Wendy, et al.. (2003). Novel Cell-specific and Dominant Negative Anti-apoptotic Roles of p73 in Transformed Leukemia Cells. Journal of Biological Chemistry. 278(4). 2249–2255. 14 indexed citations
16.
Smith, James L., Irene Collins, Gadisetti V.R. Chandramouli, et al.. (2003). Targeting Combinatorial Transcriptional Complex Assembly at Specific Modules within the Interleukin-2 Promoter by the Immunosuppressant SB203580. Journal of Biological Chemistry. 278(42). 41034–41046. 19 indexed citations
17.
Freebern, Wendy, et al.. (2002). Cross-Regulation of T Cell Growth Factor Expression by p53 and the Tax Oncogene. The Journal of Immunology. 169(12). 6767–6778. 19 indexed citations
18.
Fantappíé, Marcelo Rosado, et al.. (2001). Evaluation of Schistosoma mansoni retinoid X receptor (SmRXR1 and SmRXR2) activity and tissue distribution. Molecular and Biochemical Parasitology. 115(1). 87–99. 31 indexed citations
19.
Freebern, Wendy, et al.. (1999). Identification of a cDNA Encoding a Retinoid X Receptor Homologue from Schistosoma mansoni. Journal of Biological Chemistry. 274(8). 4577–4585. 68 indexed citations
20.
Freebern, Wendy, Edward G. Niles, & Philip T. LoVerde. (1999). RXR-2, a member of the retinoid x receptor family in Schistosoma mansoni. Gene. 233(1-2). 33–38. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Thomas G. Douglass Breakdown of academic impact, for papers by Xiaojin Xie Breakdown of academic impact, for papers by Maria A. Whitehead Breakdown of academic impact, for papers by S. Zanotta Breakdown of academic impact, for papers by Susanne Larsson Breakdown of academic impact, for papers by Shao-bing Hua Breakdown of academic impact, for papers by David Lemus Breakdown of academic impact, for papers by L.H. Tessier Breakdown of academic impact, for papers by Uwe Eberspaecher
Rankless by CCL
2026